A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6512-6521

  Syed, Samira ^a   Takimoto, Chris ^a   Hidalgo, Manuel ^a   Rizzo, Jinee ^a   Kuhn, John G ^a   Hammond, Lisa A ^a   Schwartz, Garry ^b   Tolcher, Anthony ^a   Patnaik, Amita ^a   Eckhardt, S Gail ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTINEOPLASTIC AGENT; GEMCITABINE; METALLOPROTEINASE; SUNSCREEN; TETRACYCLINE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FATIGUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER DISEASE; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHOTODERMATOSIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; SOLID TUMOR; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; TRANSAMINATION; UTERUS CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; TETRACYCLINES; TREATMENT OUTCOME;

EID: 5444229881     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0804     Document Type: Article

References (29)

1. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93.
2. Chambers AF, Matrisian LM. Changing views of the role of matrix metallaproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
3. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 1995;6:967-74.
4. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983;18:516-26.
5. Golub LM, Ramamurthy N, McNamara TF, et al. Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J Periodontal Res 1984;19:651-5.
6. Golub LM, Goodson JM, Lee HM, Vidai AM, McNamara TF, Ramamurthy NS. Tetracyclines inhibit tissue collagenases: Effects of ingested low-dose and local delivery systems. J Periodontal Res 1985; 56:93-7.
7. Golub LM, Wolff M, Lee HM, et al. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985;20:12-23.
8. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991;2:297-321.
9. Hanemaaijer R, Visser H, Koolwijk P, et al. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv Dent Res 1998;12:114-8.
10. Ramamurthy NS, Vernillo AT, Greenwald RA, et al. Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase. J Bone Miner Res 1993;8:1247-53.
11. Smith GNJ, Brandt KD, Hasty KA. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline. Ann NY Acad Sci 1994;732:436-8.
12. Smith GNJ, KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996;39:235-44.
13. Seftor REB, Seftor EA, De Larco JE, et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 16:217-25.
14. Myers SA, Wolowacz RG. Tetracycline-based MMP: Inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro. Adv Dent Res 1998;12:86-93.
15. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999;878:271-89.
16. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (Col-3) in a metastatic prostate cancer model. Int J Cancer 2002;98:297-309.
17. Selzer MG, Zhu B, Block NL, Zhu B, Lokeshwar BL. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann N Y Acad Sci 1999;878:678-82.
18. Seftor REB, Seftor EA, De Larco JE, et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998;16:217-25.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
21. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral Col-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001;19:584-92.
22. Gough K. Assessment of dose proportionality: Report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform J 1995;29:1039-48.
23. Noe DA. Noncompartmental pharmacokinetic analysis, in a clinician's guide to chemotherapy: pharmacokinetics and pharmacodynamics. LB Grochow and MM Ames, editors. Williams & Wilkins: Baltimore, 1998. pp. 515-30.
24. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Investig 1999;103: 1237-41.
25. Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 1989;9:391-405.
26. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline - a dose-related phenomenon. Clin Exp Dermatol 1993;18:425-7.
27. Hasan T, Kochevar IE, McAuliffe DJ, Cooperman BS, Abdulah D. Mechanism of tetracycline phototoxicity. J Investig Dermatol 1984;83: 179-83.
28. Miskoski S, Sanchez E, Garavano M, Lopez M, Soltermann AT, Garcia NA. Singlet molecular oxygen-mediated photo-oxidation of tetracyclines: Kinetics, mechanism and microbiological implications. J Photochem Photobiol B 1998;43:164-71.
29. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor Col-3 in the treatment of aids-related kaposi's sarcoma: A phase I aids malignancy consortium study J Clin Oncol 2002;20: 153-9.